Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600132316) titled 'A prospective, multicenter clinical study on the diagnosis of AD-related blood biomarkers in China and the evaluation of the efficacy of lencanimab' on Sept. 11.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Tianjin Huanhu Hospital
Condition:
Alzheimers disease
Intervention:
Blood test treatment group:Participants were enrolled in a prospective study
those with a positive plasma p-tau217 level (>=0.712 pg/mL) were selected and started on LEC treatment, with a follow-up period of 18 months. The subjects received treatment with lecanemab. This drug was administered a...